Benjamin Lebwohl

The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy.

BACKGROUND There are no guidelines for the recommended interval to the next examination after colonoscopy with suboptimal bowel preparation. OBJECTIVE To identify factors associated with early repeat colonoscopy after initial examinations with suboptimal preparations and to measure adenoma miss rates in this context. DESIGN Retrospective study. SETTING Hospital-based endoscopy unit. PATIENTS Bowel preparation quality was recorded in 12,787 patients. RESULTS Of 12,787 colonoscopies, preparation quality was suboptimal (poor or fair) in 3047 patients (24%). Among these 3047 patients, repeat examination was performed in <3 years in 505 (17%). Factors associated with early repeat colonoscopy included lack of cecal intubation (odds ratio [OR] 3.62, 95% confidence interval [CI], 2.50-5.24) and finding a polyp (OR 1.55, 95% CI, 1.17-2.07). Among 216 repeat colonoscopies with optimal preparation, 198 adenomas were identified, of which 83 were seen only on the second examination, an adenoma miss rate of 42% (95% CI, 35-49). The advanced adenoma miss rate was 27% (95% CI, 17-41). For colonoscopies repeated in <1 year, the adenoma and advanced adenoma miss rates were 35% and 36%, respectively. LIMITATIONS Single-center, retrospective study. CONCLUSION Although a minority of patients undergo early repeat examination after colonoscopies done with suboptimal bowel preparation, the miss rates for colonoscopies done with suboptimal bowel preparation were high, suggesting that suboptimal bowel preparation substantially decreases colonoscopy effectiveness and may mandate an early follow-up examination.

Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study.

BACKGROUND Celiac disease (CD) is associated with an increased risk for lymphoproliferative malignancy (LPM). Whether this risk is affected by the results of follow-up intestinal biopsy, performed to document mucosal healing, is unknown. OBJECTIVE To examine the association between mucosal healing in CD and subsequent LPM. DESIGN Population-based cohort study. SETTING 28 pathology departments in Sweden. PATIENTS 7625 patients with CD who had follow-up biopsy after initial diagnosis. MEASUREMENTS The risk for LPM was compared with that of the general population by using expected rates. The rate of LPM in patients with persistent villous atrophy was compared with that of those with mucosal healing by using Cox regression. RESULTS Among 7625 patients with CD and follow-up biopsy, 3308 (43%) had persistent villous atrophy. The overall risk for LPM was higher than that in the general population (standardized incidence ratio [SIR], 2.81 [95% CI, 2.10 to 3.67]) and was greater among patients with persistent villous atrophy (SIR, 3.78 [CI, 2.71 to 5.12]) than among those with mucosal healing (SIR, 1.50 [CI, 0.77 to 2.62]). Persistent villous atrophy compared with mucosal healing was associated with an increased risk for LPM (hazard ratio [HR], 2.26 [CI, 1.18 to 4.34]). The risk for T-cell lymphoma was increased (HR, 3.51 [CI, 0.75 to 16.34]) but not for B-cell lymphoma (HR, 0.97 [CI, 0.21 to 4.49]). LIMITATION No data on dietary adherence. CONCLUSION Increased risk for LPM in CD is associated with the follow-up biopsy results, with a higher risk among patients with persistent villous atrophy. Follow-up biopsy may effectively stratify patients with CD by risk for subsequent LPM.

Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma.

OBJECTIVES:Patients with villous atrophy (VA) and negative celiac disease (CD) serologies pose a diagnostic and therapeutic dilemma. When a definitive etiology for VA is not determined, patients are characterized as having unclassified sprue (US), the optimal management of which is unknown.METHODS:We studied adult patients with VA on biopsy and negative celiac serologies, evaluated at our tertiary referral center over a 10-year period. Testing for HLA DQ2/8 alleles, antienterocyte antibodies, giardia stool antigen, bacterial overgrowth, total serum immunoglobulins, and HIV was noted. Treatment, response, and repeat-biopsy findings were recorded.RESULTS:The most common diagnoses of the 72 patients were seronegative CD, medication-related villous atrophy, and US. Of those with US, the majority reported symptomatic improvement with immunosuppressive therapy. Some patients initially labeled as unclassified were found to have VA associated with olmesartan use.CONCLUSIONS:The role of medications in the development of VA and the optimal dose and length of immunosuppression for patients with US should be investigated further.

Celiac disease and non-celiac gluten sensitivity

Celiac disease is a multisystem immune based disorder that is triggered by the ingestion of gluten in genetically susceptible individuals. The prevalence of celiac disease has risen in recent decades and is currently about 1% in most Western populations. The reason for this rise is unknown, although environmental factors related to the hygiene hypothesis are suspected. The pathophysiology of celiac disease involves both the innate and adaptive immune response to dietary gluten. Clinical features are diverse and include gastrointestinal symptoms, metabolic bone disease, infertility, and many other manifestations. Although a gluten-free diet is effective in most patients, this diet can be burdensome and can limit quality of life; consequently, non-dietary therapies are at various stages of development. This review also covers non-celiac gluten sensitivity. The pathophysiology of this clinical phenotype is poorly understood, but it is a cause of increasing interest in gluten-free diets in the general population.

Adherence to biopsy guidelines increases celiac disease diagnosis

BACKGROUND Celiac disease (CD) is common but underdiagnosed in the United States. A proposed quality guideline recommends that ≥4 specimens be submitted during duodenal biopsy. The degree of adherence to this recommendation in clinical practice is unknown. OBJECTIVE To measure the number of specimens submitted during duodenal biopsy among patients throughout the United States and to determine the incremental diagnostic yield of adherence to the recommended number of specimens. DESIGN Retrospective cohort study. PATIENTS This study involved 132,352 patients without known CD who underwent duodenal biopsy. INTERVENTION Duodenal biopsy. MAIN OUTCOME MEASUREMENTS Duodenal biopsy specimens were submitted to a pathology laboratory operating in 43 states in the United States. We used multivariate logistic regression to identify factors associated with submitting ≥4 specimens. We also compared the prevalence of newly diagnosed CD in biopsies with ≥4 specimens with that in biopsies with <4 specimens. RESULTS Of the 132,352 patients who underwent biopsy (67% women, mean age 52.9 years), ≥4 specimens were submitted in 45,995 cases (35%). A modest increase in the proportion of biopsies with ≥4 specimens occurred after this guideline was proposed in 2006 (odds ratio for 2009 vs 2006, 1.51; 95% confidence interval, 1.22-1.88), but the rate of adherence in 2009 remained low at 37%. Among patients in whom the indication was malabsorption/suspected CD (n = 3261), adherence to this standard was only 39.5%. The probability of a new diagnosis of CD was increased when ≥4 specimens were submitted (1.8% vs 0.7%; P < .0001). LIMITATIONS Retrospective analysis lacking clinical follow-up. The guideline publication occurred during the study period, possibly influencing clinical practice and confounding results. CONCLUSION Although this proposed standard remains a subject of debate, adherence to submitting ≥4 specimens is low in the United States. Adherence yields a diagnosis rate of 1.8%, a small absolute increase but a doubling of the diagnosis rate of CD. Efforts to increase adherence are warranted.

Antibiotic exposure and the development of coeliac disease : a nationwide case-control study

BackgroundThe intestinal microbiota has been proposed to play a pathogenic role in coeliac disease (CD). Although antibiotics are common environmental factors with a profound impact on intestinal microbiota, data on antibiotic use as a risk factor for subsequent CD development are scarce.MethodsIn this population-based case–control study we linked nationwide histopathology data on 2,933 individuals with CD (Marsh stage 3; villous atrophy) to the Swedish Prescribed Drug Register to examine the association between use of systemic antibiotics and subsequent CD. We also examined the association between antibiotic use in 2,118 individuals with inflammation (Marsh 1–2) and in 620 individuals with normal mucosa (Marsh 0) but positive CD serology. All individuals undergoing biopsy were matched for age and sex with 28,262 controls from the population.ResultsAntibiotic use was associated with CD (Odds ratio [OR] = 1.40; 95% confidence interval [CI] = 1.27-1.53), inflammation (OR = 1.90; 95% CI = 1.72–2.10) and normal mucosa with positive CD serology (OR = 1.58; 95% CI = 1.30–1.92). ORs for prior antibiotic use in CD were similar when we excluded antibiotic use in the last year (OR = 1.30; 95% CI = 1.08-1.56) or restricted to individuals without comorbidity (OR = 1.30; 95% CI = 1.16 – 1.46).ConclusionsThe positive association between antibiotic use and subsequent CD but also with lesions that may represent early CD suggests that intestinal dysbiosis may play a role in the pathogenesis of CD. However, non-causal explanations for this positive association cannot be excluded.

Infliximab for the treatment of hidradenitis suppurativa

We describe a patient with hidradenitis suppurativa whose lesions responded to the administration of infliximab for suspected Crohns disease.

Colonoscopic Screening in Average-Risk Individuals Ages 40 to 49 vs 50 to 59 Years

BACKGROUND & AIMS Screening guidelines for colorectal cancer include colonoscopy starting at age 50 years based on the prevalence of adenomas and the incidence of colon cancer at that age. However, only one prior study has investigated the prevalence of colorectal neoplasia with colonoscopic screening in asymptomatic average-risk individuals ages 40-49 years in the United States. METHODS We analyzed the results of screening colonoscopies offered to patients of a health care provider that offers screening services as part of an employer-provided wellness program. The primary end points were prevalence of adenomas and cancers for those aged 40-49 years vs those 50-59 years. RESULTS We analyzed 553 screening colonoscopies for patients ages 40-49 years and 352 screening colonoscopies for patients ages 50-59 years. In the 40-49 years age group, 79 patients (14%) had 1 or more adenomas, of which 11 (2% of screened) had an advanced neoplasm (>1 cm). In the 50-59 years age group, 56 patients (16%) had 1 or more adenomas detected. Of those patients, 13 (3.7% of screened) had an advanced neoplasm, and 1 patient (0.3%) had an adenocarcinoma detected. CONCLUSIONS We found on colonoscopic screening that the prevalence of total adenomas was similar in individuals ages 40-49 and in those 50-59 years, although the prevalence of advanced neoplasia in the 50-59 years age group may be higher than that in the 40-49 years age group.

Screening for celiac disease in average-risk and high-risk populations

The prevalence of celiac disease is rising. As a result there is increasing interest in the associated mortality and morbidity of the disease. Screening of asymptomatic individuals in the general population is not currently recommended; instead, a strategy of case finding is the preferred approach, taking into account the myriad modes of presentation of celiac disease. Although a gluten-free diet is the treatment of choice in symptomatic patients with celiac disease, there is no consensus on whether institution of a gluten-free diet will improve the quality of life in asymptomatic screen-detected celiac disease patients. A review of the studies that have been performed on this subject is presented. Certain patient groups such as those with autoimmune diseases may be offered screening in the context of an informed discussion regarding the potential benefits, with the caveat that the data on this issue are sparse. Active case finding seems to be the most prudent option in most clinical situations.

Mucosal healing and mortality in coeliac disease.

Coeliac disease (CD), characterised by the presence of villous atrophy (VA) in the small intestine, is associated with increased mortality, but it is unknown if mortality is influenced by mucosal recovery.